Therefore, NK-92-S3KD cell also represents as a promising cell therapy in combination with ICIs or other immunotherapies given its robust cytotoxicity against cancer cells and powerful immunomodulatory capacity in the TGF-β-rich microenvironment. This evidence concerns the gene TGFB1 and cancer.